Dr. D’Angelo on Future Directions With CAR T-Cell Therapy in Lymphoma

Video

Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.

Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses advances made with CAR T-cell therapy in lymphoma.

Recently, it has been possible to achieve durable remissions and complete responses with CAR T-cell therapy in this patient population, D’Angelo says. This could indicate that this modality may represent a potential curable approach for a refractory population, according to D’Angelo.

Safer CAR T-cell products with increased efficacy and complete, durable responses, are anticipated, D'Angelo notes.

Additionally, the emergence of novel CAR T-cell therapy combinations with agents such as lenalidomide (Revlimid) and ibrutinib (Imbruvica), possess potential, D’Angelo concludes. 

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Guenther Koehne, MD, PhD
Lori A. Leslie, MD, an expert on lymphoma
Lori A. Leslie, MD, an expert on lymphoma
A panel of 4 experts on MDS
Elias Jabbour, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD